Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Among the cases of nephrotic syndrome associated with solid tumors, membranous nephropathy is well recognized. Meanwhile, although only a limited number of cases, minimal change disease (MCD) has been reported in patients with malignant pleural mesothelioma (MPM). However, it remains unclear whether MCD is truly associated with MPM or merely coincidental.
A 67-year-old Japanese man rapidly developed a cough and bilateral leg edema over a month, and visited his local doctor. Laboratory tests revealed newly developed massive proteinuria and hypoalbuminemia. Chest X-ray showed a massive right pleural effusion, and computed tomography revealed pleural tumors. He underwent a pleural tumor biopsy, which confirmed the diagnosis of MPM. He was started on platinum-based chemotherapy, but it was discontinued after 8 months due to declining renal function, with serum creatinine increasing from 0.98 to 1.66 mg/dL, prompting a referral to the nephrology department. He presented with 13.07 g/day of proteinuria and hypoalbuminemia, consistent with nephrotic syndrome. Serological testing for nephritis was unremarkable. A kidney biopsy revealed MCD, along with probable cisplatin-associated tubulointerstitial injury.
Considering the possibility that MCD was associated with MPM, we decided to prioritize systemic therapy over steroids and initiate second-line treatment for MPM with nivolumab. After initiation of nivolumab, the pleural tumors regressed within 4 months. Proteinuria gradually improved, achieving partial remission at 8 months and subsequent complete remission at 23 months. At 29 months after nivolumab initiation, a new pleural tumor was noted. Concurrently, proteinuria levels increased to 0.45 g/gCr. Salvage radiotherapy led to a reduction in tumor size, and proteinuria subsequently resolved. He remains negative for proteinuria at 48 months of follow-up, and his renal function has shown no significant change throughout the period.
This case represents a rare report detailing the therapeutic course of MCD associated with MPM. In this case, nephrotic syndrome achieved complete remission as the MPM regressed, and proteinuria recurred with tumor progression. These observations strongly indicate that the patient’s MCD was a paraneoplastic phenomenon of the underlying MPM. Notably, in this case, serum VEGF levels fluctuated in parallel with the disease activity of MPM and the clinical course of MCD. Further studies are warranted to elucidate whether VEGF plays a pathogenic role in MPM-associated MCD. With advances in the treatment and improved prognosis of MPM, clinicians should recognize that successful systemic tumor control is the key to achieving remission of paraneoplastic kidney diseases.
